Roche Holding AG (XSWX:RO) Asset Impairment Charge: CHF0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:RO Roche Holding AG XSWX:RO
76 GF Score
Price CHF358.60
GF Value CHF270.12
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Asset Impairment Charge?

Roche Holding AG XSWX:RO -0.06% 76 Asset Impairment Charge is CHF0 Mil as of Jun. 2026. GuruFocus rates XSWX:RO with a GF Score™ of 76/100 and a GF Value™ of CHF270.12 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Roche Holding AG's Asset Impairment Charge for the six months ended in Jun. 2026 was CHF0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was CHF0 Mil.

Roche Holding AG Asset Impairment Charge Related Terms

Roche Holding AG Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Asset Impairment Charge Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Roche Holding AG Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:RO
76GF Score
Roche Holding AG XSWX:RO
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0 Mil.

What does a Asset Impairment Charge of CHF0 Mil mean?
Roche Holding AG (XSWX:RO) has a Asset Impairment Charge of CHF0 Mil as of Jun. 2026.
Is Roche Holding AG's Asset Impairment Charge too high?
Roche Holding AG's current Asset Impairment Charge is CHF0 Mil. Overall, Roche Holding AG has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Asset Impairment Charge compare to LLY and JNJ?
Roche Holding AG's Asset Impairment Charge of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Drug Manufacturers company?
A good Asset Impairment Charge depends on the Drug Manufacturers industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Roche Holding AG's current Asset Impairment Charge is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF270.12, compared to a current price of CHF358.60 — trading 32.8% above its estimated fair value. The current Asset Impairment Charge is CHF0 Mil. Roche Holding AG's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Asset Impairment Charge is CHF0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:RO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF358.60 is trading 32.8% above its estimated GF Value™ of CHF270.12. GuruFocus considers Roche Holding AG to be Significantly Overvalued.

Key valuation signals for XSWX:RO:

  • Asset Impairment Charge: CHF0 Mil
  • GF Value™: CHF270.12 vs. price of CHF358.60 (32.8% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
76GF Score

Get the complete analysis for XSWX:RO

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF358.60
Price
CHF270.12
GF Value